Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy

Cancer microenvironment is critical for tumorigenesis and cancer progression. The extracellular matrix (ECM) interacts with tumor and stromal cells to promote cancer cells proliferation, migration, invasion, angiogenesis and immune evasion. Both ECM itself and ECM stiffening-induced mechanical stimuli may activate cell membrane receptors and mechanosensors such as integrin, Piezo1 and TRPV4, thereby modulating the malignant phenotype of tumor and stromal cells. A better understanding of how ECM stiffness regulates tumor progression will contribute to the development of new therapeutics. The rapidly expanding evidence in this research area suggests that the regulators and effectors of ECM stiffness represent potential therapeutic targets for cancer. This review summarizes recent work on the regulation of ECM stiffness in cancer, the effects of ECM stiffness on tumor progression, cancer immunity and drug resistance. We also discuss the potential targets that may be druggable to intervene ECM stiffness and tumor progression. Based on these advances, future efforts can be made to develop more effective and safe drugs to interrupt ECM stiffness-induced oncogenic signaling, cancer progression and drug resistance.

Automated summary

The cancer microenvironment plays a critical role in tumorigenesis and cancer progression. The interaction between the extracellular matrix (ECM) and tumor and stromal cells contributes to cancer cell proliferation, migration, invasion, angiogenesis, and immune evasion. Both ECM stiffness itself and ECM stiffening-induced mechanical stimuli can activate cell membrane receptors and mechanosensors, thereby modulating the malignant phenotype of tumor and stromal cells. Understanding how ECM stiffness regulates tumor progression is crucial for the development of new therapeutics.